<DOC>
	<DOC>NCT00287508</DOC>
	<brief_summary>To collect clinical outcome and device performance data on the FDA 510(k)-cleared Emboshield® BareWire™ Rapid Exchange Embolic Protection System and FDA-approved Xact® Rapid Exchange Carotid Stent System when used under commercial use conditions by a broad group of physicians entering the study with differing carotid artery stenting experiences.</brief_summary>
	<brief_title>Emboshield® and Xact® Post Approval Carotid Stent Trial (The EXACT Study)</brief_title>
	<detailed_description>This is a multi-center, observational, single arm, post-approval study enrolling the following study population: - Subjects with neurological symptoms and &gt;= 50% stenosis of the common or internal carotid artery by ultrasound or angiogram (visual estimate), or - Subjects without neurological symptoms and &gt;= 80% stenosis of the common or internal carotid artery by ultrasound or angiogram (visual estimate) - The endpoint for the 1500 subjects enrolled will be a 30-day composite of death, stroke and myocardial infarction (MI). - For the 500 subjects with 12 month follow-up, the endpoint will be a composite of stroke, death and MI at 30 days and ipsilateral stroke at 12 months (31-365 days).</detailed_description>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Carotid Artery Diseases</mesh_term>
	<mesh_term>Carotid Stenosis</mesh_term>
	<criteria>Subjects who agree to participate in this study and have signed the IRB approved informed consent form. Subjects who are willing to have the Emboshield and/or the Xact inserted into the their vasculature. There are no exclusion criteria for this study.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Carotid stenting</keyword>
	<keyword>Carotid endarterectomy</keyword>
	<keyword>Carotid artery disease with severe narrowing of the artery</keyword>
	<keyword>Stroke prevention</keyword>
	<keyword>cerebral infarction</keyword>
</DOC>